Sodium Channel Blockers Demonstrate Binding Affinity for the Tandem Tudor Domain of the Epigenetic Hub UHRF1
ChemMedChem · 2026
DOI: 10.1002/cmdc.70473 ↗At a glance
Journal article in ChemMedChem, 2026. Written by Efstratios Tsakalidis and 16 co-authors. Institution: Division of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece. Major MEDLINE topics: CCAAT-Enhancer-Binding Proteins, Ubiquitin-Protein Ligases, Sodium Channel Blockers, Antineoplastic Agents. 85 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
The tandem Tudor domain (TTD) of UHRF1 is a compelling epigenetic target for novel cancer therapeutics. Here, we integrate theoretical simulations, sophisticated biophysical evaluations and cellular assays to characterize potent TTD binders. Screening of small drug‐ and fragment‐like collections identifies several TTD ligands, with the most promising hit being the local anesthetic hydroxyprocaine. The ligand is characterized in terms of its binding requisites by calorimetry, affording a K d of 1.46 μM and a well‐balanced thermodynamic profile. Molecular dynamics simulations combined with heat capacity measurements and osmotic stress titrations confirm that hydroxyprocaine binds stably to the TTD by displacing approximately 26 interfacial water molecules upon complexation. A targeted follow‐up screen focusing on sodium channel blockers yields two additional, although less promising hits, mexiletine and triamterene. In the DU145 prostate cancer cell line, hydroxyprocaine treatment significantly up‐regulates key downstream targets including the tumor‐suppressor p53 and, to a lesser degree, the stress and inflammation regulators p38 and p65, respectively, while exhibiting very low cytotoxicity. Finally, a previously undocumented interdomain interaction between TTD and its N‐terminal adjacent Ubiquitin‐like domain is reported, introducing a novel, potentially druggable UHRF1 regulatory feature. Together, these findings establish hydroxyprocaine as a highly viable chemical scaffold for TTD‐targeted drug development.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
- Laboratory of Analytical Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
- Laboratory of Inorganic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Biology, National and Kapodistrian University of Athens, Athens, Greece.
ORCID profiles: Efstratios Tsakalidis, Ifigeneia Akrani, Anthi Panara, Kyriaki Degaita, Panagiota Efstathia Nikolaou, Emmanuel Mikros, Evangelos Gikas, Eleni K Efthimiadou, Vassilios Myrianthopoulos
Cite
APA
Tsakalidis, E., Giannouli, M., Akrani, I., Panara, A., Katalagarianou, E., Degaita, K., Giahou, M., Kyriakou, K., Routsi, M., Nikolaou, P. E., Tsitsou, E., Tsoka, A., Vorgias, C. C., Mikros, E., Gikas, E., Efthimiadou, E. K., & Myrianthopoulos, V. (2026). Sodium Channel Blockers Demonstrate Binding Affinity for the Tandem Tudor Domain of the Epigenetic Hub UHRF1. ChemMedChem. https://doi.org/10.1002/cmdc.70473
Vancouver
Tsakalidis E, Giannouli M, Akrani I, Panara A, Katalagarianou E, Degaita K, et al. Sodium Channel Blockers Demonstrate Binding Affinity for the Tandem Tudor Domain of the Epigenetic Hub UHRF1. ChemMedChem. 2026. doi:10.1002/cmdc.70473
BibTeX
@article{Tsakalidis2026,
author = {Tsakalidis, Efstratios and Giannouli, Mariangela and Akrani, Ifigeneia and Panara, Anthi and Katalagarianou, Eleni and Degaita, Kyriaki and Giahou, Maria and Kyriakou, Konstantina and Routsi, Maria and Nikolaou, Panagiota Efstathia and Tsitsou, Evangelia and Tsoka, Aggeliki and Vorgias, Constantinos C and Mikros, Emmanuel and Gikas, Evangelos and Efthimiadou, Eleni K and Myrianthopoulos, Vassilios},
title = {Sodium Channel Blockers Demonstrate Binding Affinity for the Tandem Tudor Domain of the Epigenetic Hub UHRF1},
journal = {ChemMedChem},
year = {2026},
doi = {10.1002/cmdc.70473}
}
EUVIMED